PALO ALTO, Calif., May 21, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, announced today that company management plans to present at the Jefferies 2014 Global Healthcare Conference. Ocera's presentation is scheduled for Thursday, June 5, 2014 at 1:30 PM ET. A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com . A replay of the presentation will be available for 30 days following the conference for those unable to listen live. About Ocera Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger under development for the treatment of hyperammonemia and associated hepatic encephalopathy in patients with liver cirrhosis, acute liver failure and acute liver injury. The FDA has granted Orphan Disease and Fast Track status to OCR-002. For additional information, please see www.ocerainc.com .
CONTACT: Inquiries: Jeri Hilleman Ocera Therapeutics, Inc. Communications@ocerainc.com 650-475-0158